Campbell & CO Investment Adviser LLC

Position in GRFS — Grifols SA

CIK 1353570 BALTIMORE, MD

Position in GRFS

as of Jun 30, 2026 · filed Aug 3, 2026 Compact

Position Value

$791,041

+$278,981 QoQ

Shares Held

111,729

+75.0% QoQ

Ownership

0.016%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

#46

of 164 holders

Holding Since

Jun 2020

12 quarters on record

Voting authority Sole 0% Shared 0% None 100%

Healthcare · as of Jun 30, 2026

Campbell & CO Investment Adviser LLC holds $29,426,907 across 9 Drug Manufacturers - General names. GRFS ranks #9 (2.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	AMGN	Amgen Inc	18,379	$6,655,403
2	AZN	Astrazeneca PLC	29,025	$5,503,720
3	LLY	ELI LILLY & Co	3,682	$4,416,301
4	GSK	GSK plc	83,989	$4,402,703
5	SNY	Sanofi	52,949	$2,258,804
6	GILD	Gilead Sciences, Inc.	17,781	$2,246,451
7	PFE	Pfizer Inc	75,099	$1,808,383
8	BMY	Bristol Myers Squibb Co	23,327	$1,344,101

12 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$791,041	111,729	+75.0%	Shares	Sole	2026-08-03
2026-03-31	$512,060	63,848	-31.4%	Shares	Sole	2026-05-15
2025-12-31	$870,802	93,134	-20.2%	Shares	Sole	2026-02-12
2025-09-30	$1,162,351	116,702	+6.6%	Shares	Sole	2025-10-28
2025-06-30	$989,554	109,464	+516.4%	Shares	Sole	2025-08-07
2025-03-31	$126,259	17,758	-91.7%	Shares	Sole	2025-05-14
2024-09-30	$1,907,672	214,828	+473.0%	Shares	Sole	2024-11-12
2024-06-30	$236,593	37,495	-29.0%	Shares	Sole	2024-08-13
2023-12-31	$610,483	52,810	+63.4%	Shares	Sole	2024-02-13
2023-03-31	$238,161	32,315	+2.4%	Shares	Sole	2023-05-11
2022-09-30	$194,465	31,569	+189.8%	Shares	Sole	2022-11-14
2020-06-30	$198,724	10,895	—	Shares	Sole	2020-07-29
No filing history on record for this holder in this stock.